GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17%

GSK plc (NYSE:GSK) ranks among the best undervalued European stocks to buy now. On February 4, GSK plc (NYSE:GSK) announced fourth-quarter earnings that outperformed analyst estimates in several important metrics. Earnings per share for the quarter came in at $0.6989, 9.58% more than the forecast of $0.6378. Revenue also surpassed forecasts, coming in at $11.81 billion versus $11.36 billion, for a 3.96% upside surprise.

Pixabay/Public Domain

Specialty Medicines was a fairly promising area, with 17% growth, while Oncology outperformed expectations, with sales up 43% from the same quarter last year.

GSK plc (NYSE:GSK) issued upbeat guidance for 2026, projecting 3-5% sales growth. The company forecasts core operating profit and earnings per share to rise even faster, at 7-9%, implying further margin expansion. The company’s management stated that oncology and respiratory medicines, as well as expanding pipeline assets, will be the main drivers of future growth.

GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company that researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

This article is originally published at Insider Monkey.